TAE LIFE SCIENCES

Investors & News

9/2021 | Business Wire

TAE Life Sciences Partners with BEC to Incorporate Specialized Robotic Patient Positioning System in its Alphabeam™ System for High-Precision Boron Neutron Capture Therapy

During BNCT, it is essential that the patient is positioned accurately in relation to the radiation beam and that the radiation therapist has the ability to adjust the patient’s position throughout the whole treatment session. BEC will be developing a unique chair setup that will allow for flexible patient treatment in a seated position in addition to the traditional treatment couch configuration. Exclusively designed for TLS’ Alphabeam™ Neutron System, the chair is optimal for treating specific types of head and neck cancers.

9/2021 | Businesswire

TAE Life Sciences Announces Installation of First Accelerator-based Neutron Beam System for Biologically Targeted Radiation Therapy at Xiamen Humanity Hospital in China

TLS’ Neutron Beam System enables a new treatment modality for patients diagnosed with the most aggressive and recurrent cancers such as gliomas, head and neck tumors, and melanomas, by delivering more precise, targeted radiation to cancer cells while sparing damage to surrounding healthy tissue. This technique holds promise in treating patients with cancer for whom other treatment options have been exhausted or are unavailable.

7/2021 | Businesswire

TAE Life Sciences Announces Scientific Advisory Board to Advance Cancer Research in Boron-Neutron Capture Therapy

BNCT is unique in its ability to deliver targeted therapy to destroy cancer cells with biological precision and has shown compelling results in treating some of the most challenging cancers, including brain, head and neck tumors and melanomas. BNCT uses the benign boron-10 isotope in a targeting drug that naturally embeds within fast-growing cancer cells, which then receive an intense, highly localized dose of radiation activated by a low-energy neutron beam.

TLS in the News

Events

Developing targeted drugs for boron neutron capture therapy to treat refractory cancers

Developing targeted drugs for boron neutron capture therapy to treat refractory cancers

TAE Life Sciences is developing a next-generation boron neutron capture therapy for cancer. After recently introducing Alphabeam, a compact and affordable accelerator-based neutron system suitable for hospital settings, the company is now focusing on the development of novel boron drugs with improved tumor selectivity and increased 10B loads.

VIDEO: Explaining Boron Neutron Capture Therapy for Targeted Cancer Radiotherapy

VIDEO: Explaining Boron Neutron Capture Therapy for Targeted Cancer Radiotherapy

Bruce Bauer, Ph.D., CEO of TAE Life Sciences. The company is developing boron neutron capture therapy (BNCT) as a new radiation therapy for cancer. A patient is first infused with a non-toxic boron-10 compound, which selectively accumulates in tumor tissue. A neutron beam is then focused on the tumor and the neutrons are captured by the boron and causes emission of alpha radiation particles within the tumor.

RaySearch and TAE Life Sciences Announce Agreement on RayStation Support for the Alphabeam System for BNCT

RaySearch and TAE Life Sciences Announce Agreement on RayStation Support for the Alphabeam System for BNCT

BNCT is a biologically targeted radiation therapy that kills cancer at the cellular level. The technique uses a two-step process. In the first step, patients are injected with a tumor-targeting drug that contains non-toxic and non-radioactive boron-10.

$30M for Cancer-Focused TAE Life Sciences

$30M for Cancer-Focused TAE Life Sciences

HEALTHCARE: SPIN-OFF FROM FUSION COMPANY AIMING BIG

Tiny Yet Mighty: Nanotechnology in Radiation Therapy

Tiny Yet Mighty: Nanotechnology in Radiation Therapy

Nanotechnology is the application of extremely small things—a nanometer is one billionth of a meter—used in science, engineering and technology. It involves the ability to view and control individual atoms and molecules and has been used in designing new therapeutics and diagnostics in medicine. As such, interest is mounting to harness nanotechnology’s potential to enhance radiation therapy and advance cancer care.

New TAE Unit Launched To Treat Cancers Gains $40M In Financing And Closes Partnership Deal

New TAE Unit Launched To Treat Cancers Gains $40M In Financing And Closes Partnership Deal

BNCT may provide a new option for patients with GBM and head and neck cancers due to its ability to leave healthy tissue unharmed.

TAE Life Sciences Inks $40M Series A Funding

TAE Life Sciences Inks $40M Series A Funding

TAE Life Sciences, a medical technology company developing an accelerator-based platform for clinical investigation of a promising, previously inaccessible cancer treatment, made its public debut today.

TAE Life Sciences Raises $40M For Neutron Beam Cancer Treatment

TAE Life Sciences Raises $40M For Neutron Beam Cancer Treatment

TAE Life Sciences said yesterday it raised $40 million in venture capital to support the development of its neutron beam technology designed as a potential treatment for head and neck, glioblastoma multiforme and other cancers.

TAE Raises $40M To Develop New Targeted Radiotherapy

TAE Raises $40M To Develop New Targeted Radiotherapy

Medtech firm TAE Life Sciences is developing a ground-breaking radiotherapy technology which will be able to treat hard-to-reach cancers with targeted beams.

$40 Million for Boron Neutron Capture Therapy

$40 Million for Boron Neutron Capture Therapy

TAE Life Sciences aims to commercialize a cancer radiation treatment called Boron Neutron Capture Therapy. In BNCT, boron-10 is administered to tumors, irradiated with a beam of neutrons, and broken down into charged particles that kill cancer cells.

A Surprise Application To Cancer

A Surprise Application To Cancer

There’s a radiological medical technique called Boron Neutron Capture Therapy (BNCT), which is like a very targeted chemotherapy.

TAE Life Sciences Is Trying To Make Boron Neutron Capture Therapy More Accessible

TAE Life Sciences Is Trying To Make Boron Neutron Capture Therapy More Accessible

The neutron beam is aimed at the cancer patient’s tumors for about 30 minutes, and is combined with a boron-based substance that is injected into the patient intravenously and accumulates in the cancer cells.

ESTRO 2022

ESTRO 2022

May 6-10, 2022

Copenhagen, Denmark

The ambition of ESTRO to further reinforce radiation oncology as a core partner in multidisciplinary cancer care, and to guarantee accessible and high-value radiation therapy for all cancer patients who need it, is expressed in the society’s vision statement for 2030: ‘Radiation Oncology. Optimal Health for All, Together.’. After a difficult couple of years, this is more poignant than ever as, in 2022, we expect to again be able to freely get together and connect.

ASTRO Annual Meeting 2022

ASTRO Annual Meeting 2022

October 23-26, 2022

San Antonio, TX

Mark your calendar now for the 64th ASTRO Annual Meeting! This is the premier radiation oncology scientific event in the world with more than 11,000 attendees each year. The 2022 ASTRO Annual Meeting—AI and EI: Caring for Patients in a Wireless World—will include a full program with engaging educational and scientific sessions, live SA-CME courses and networking events. We’ll highlight the potential of AI, Big Data and scientific advances while showcasing the central role of human interaction in caring for and curing our patients! We’re excited to continue popular offerings from recent years – such as expanded Cancer Breakthroughs sessions and Storytelling – along with deeper dives into important topics with our Master Class series.